newsfilter
← Earnings
Earnings Releases·

Prelude Therapeutics — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Revenue for the three months ended September 30, 2026, was $5.647 million, a decrease from $6.5 million in the same period of 2025.
    • Net loss for the three months ended September 30, 2026, was $12.544 million ($0.12 per share), compared to a net loss of $19.725 million ($0.26 per share) in the prior year period.
    • Research and Development (R&D) expenses decreased to $14.83 million for the three months ended September 30, 2026, from $21.708 million in the prior year period.
    • General and Administrative (G&A) expenses decreased to $5.082 million for the three months ended September 30, 2026, from $5.21 million in the prior year period.
    • Cash, cash equivalents, restricted cash, and marketable securities totaled $142.7 million as of September 30, 2026.
    • Operating lease liabilities were $2.796 million (current) and $14.763 million (non-current) as of September 30, 2026.
    • Deferred revenue decreased to $19.601 million (current) with no non-current portion as of September 30, 2026, compared to $33.734 million (current) and $1.798 million (non-current) as of December 31, 2025.
    • Total stockholders' equity increased to $124.136 million as of September 30, 2026, from $68.637 million as of December 31, 2025.
  • Guidance and Future Outlook:

    • The Company anticipates its existing cash runway will fund operations into the second quarter of 2028.
    • Initial proof of concept data for the Phase 1 study of PRT13722 in HR+ breast cancer is anticipated in the second half of 2027.
    • Multiple clinical readouts are expected over the next 12 to 18 months.
    • The JAK2V617F inhibitor program is subject to an exclusive option agreement with Incyte expiring in February 2027, with a potential 3-month extension.
  • Business Segments and Product Lines:

    • Enrollment is underway for the Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer.
    • The Company entered a clinical trial collaboration and supply agreement with Eli Lilly and Company to evaluate PRT13722 in combination with abemaciclib and imlunestrant in HR+/HER2- breast cancer.
    • Enrollment continues in the Phase 1 study of PRT12396, a mutant-selective JAK2V617F inhibitor, in patients with polycythemia vera (PV) and myelofibrosis (MF).
    • Preclinical data from the mCALR-targeted degrader antibody conjugate (DAC) lead development candidate was accepted for presentation at the ASH 68th Annual Meeting.
    • The SMARCA2 clinical trials were paused in 2025, contributing to lower R&D expenses.
    • The Company is leveraging degrader payloads for next-generation DACs, with potential for licensing to additional partners.
  • Market and Competitive Landscape:

    • JAK2V617F is the primary driver mutation in approximately 95% of PV, 60% of ET, and 55% of MF patients.
    • Mutant CALR is found in approximately 25-35% of MF and ET patients.
    • KAT6 is an emerging and recently validated target in the treatment of HR+ breast cancer.
    • The Company believes its mutant-selective JAK2 inhibitors may reduce mutant allele burden and reverse disease progression compared to existing treatments.
  • Risks and Challenges:

    • Clinical trial results, regulatory approvals, and commercialization timelines are inherently uncertain.
    • Risks include the ability to advance product candidates, enroll eligible patients, and maintain supply chain and manufacturing facilities.
    • The Company faces risks related to funding development activities and achieving development goals.
    • Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ significantly from expectations.
  • Management Commentary and Tone:

    • CEO Kris Vaddi described the first three quarters of 2026 as a period of "strong execution."
    • Management highlighted the rapid advancement of two first-in-class programs (PRT12396 and PRT13722) into clinical development.
    • The Company expressed confidence in being well-positioned to enter 2027 with momentum to drive future growth.
    • Management noted the decrease in R&D expenses was primarily due to the pause of SMARCA2 trials and a workforce reduction in the second half of 2025.
  • Other Key Points:

    • The Company will participate in the 9th Annual Evercore Healthcare Conference on December 2, 2026, with a fireside chat featuring CEO Kris Vaddi, CSO Peggy Scherle, and CFO Bryant Lim.
    • Updated preclinical data for PRT13722 and the mCALR DAC program will be presented at the 2026 San Antonio Breast Cancer Symposium and the ASH 67th Annual Meeting, respectively.
    • The Company has published preclinical data demonstrating that next-generation DACs using its degrader payloads show potential for better in vivo efficacy and tolerability compared to traditional cytotoxic ADCs.
    • The number of weighted average common shares outstanding increased to 103,091,149 in Q3 2026 from 76,132,337 in the prior year period.
Company
PRELUDE THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology